Uterine myoma: A condition amendable to medical therapy?

Expert Opinion on Emerging Drugs

Volumn 13, Issue 1, 2008, Pages 119-133

  Cheng, Ming Hui ^a   Wang, Peng Hui ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Fibroids; Leiomyomata; Medical therapy; Uterine myomas

Indexed keywords

11BETA (4 ACETYLPHENYL) 17BETA HYDROXY 17ALPHA (1,1,2,2,2 PENTAFLUOROETHYL)ESTRA 4,9 DIEN 3 ONE; ABARELIX; ANASTROZOLE; ASOPRISNIL; CABERGOLINE; CETRORELIX; CLOMIFENE; DANAZOL; GANIRELIX; GASTRINONE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; IDOXIFENE; J 1042; J 956; LAUREATIDE; LEUPRORELIN; LEVONORGESTREL; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TESTOSTERONE DERIVATIVE; TIBOLONE; ULIPRISNIL ACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERALIPRIDE;

CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIAL DISEASE; FEMALE; HOT FLUSH; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LEIOMYOMA; MEDLINE; MENSTRUAL IRREGULARITY; OVARY CYST; PATIENT MONITORING; REVIEW; TUMOR VOLUME; UTERUS MYOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LEIOMYOMA; MYOMA; UTERINE NEOPLASMS;

EID: 41349099683     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.1.119     Document Type: Review

References (191)

1. Hashimoto K, Azuma C, Kamiura K, et al. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest 1995;40:204-8
2. Lurie S, Piper I, Woliovitch I, Glezerman M. Age-related prevalence of sonographically confirmed uterine myomas. J Obstet Gynaecol 2005;25:42-4
3. Marino JL, Eskenazi B, Warner M, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Repord 2004;19:2350-5
4. Lippman SA, Warner M, Samuels S, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003;80:1488-94
5. Baird DD, Hill MC, Cousins D, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7
6. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111:1037-54
7. Chalas E, Constantino JP, Wickerham DL, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005;192:1230-7
8. Schwartz S. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001;44:316-26
9. Choen O, Schindel B, Homburg R. Uterine leiomyomata - a feature of acromegaly. Hum Reprod 1998;13:1945-6
10. Grattarola R, Li CH. Effect of growth hormone and its combination with estradiol-17β on the uterus of hypophysectomized-ovariectomized rats. Endocrinology 1959;65:802-10
11. Ligon A, Morton CC. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update 2001;7:8-14 • This paper reviews the cytogenetic aberrations and gene expression with respect to their contributions to the pathogenesis of leiomyomata, and also summarizes the current understanding of heritability of these tumors.
12. Van Voorhis BJ, Romitti PA, Jones MP. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. J Reprod Med 2002;47:663-9
13. Stewart E. Uterine fibroids. Lancet 2001;357:293-8
14. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7
15. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 2005;158:1-199
16. Sabbour SM. Epidemiological correlates of hysterectomy, a hospital based study 1995-1996 at Ain Shams Maternity Hospital. J Egypt Public Health Assoc 2001;76:71-87
17. Wallach E, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004;104:393-406 • The authors review the biology and the pathophysiology of uterine myomas, focus on options for management, and emphasize principles that will render the decision-making process as logical as possible.
18. Jacobson GF, Shaber RE, Armstrong MA, Hung YY. Hysterectomy rates for benign indications. Obstet Gynecol 2006;107:1278-83
19. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002;99:229-34
20. Luoto R, Kaprio J, Keskimaki I, et al. Incidence, causes, and surgical methods for hysterectomy in Finland. 1987-1989. Int J Epidemiol 1994;23:348-58
21. Chryssikopoulos A, Loghis C. Indications and results of total hysterectomy. Int Surg 1986;71:188-94
22. Lee WL, Liu RS, Yuan CC, et al. Relationship between gonadotropin- releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography. Fertil Steril 2001;75:638-9
23. Liu WM, Wang PH. Reply. Fertil Steril 2007;88:759
24. Liu WM, Wang PH, Chou CS, et al. Uterine artery ligation for treatment of pregnant women with uterine leiomyomas who are undergoing cesarean section. Fertil Steril 2007;86:423-8
25. Liu WM, Tzeng CR, Yi-Jen Chen, Wang PH. Combining the uterine depletion procedure and myomectomy may be useful for treating symptomatic fibroids. Fertil Steril 2004;82:205-10
26. Wen KC, Sung PL, Chao KC, et al. A prospective short-term evaluation of uterine leiomyomas treated by myomectomy through conventional laparotomy or ultramini-laparotomy. Fertil Steril In press
27. Su WH, Cheung SM, Chang SP, Lee WL. Internal bleeding from a ruptured serosa vein covering the myoma surface mimicking upper gastrointestinal bleeding. Taiwan J Obstet Gynecol 2008;47:In press
28. Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003;101:431-7
29. Stovall D. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol 2001;44:364-71
30. Koutsilieris M. Pathophysiology of uterine leiomyomata. Biochem Cell Biol 1992;70:273-8
31. Hickey M, Fraser IS. Clinical implications of disturbances of uterine vascular morphology and function. Baillieres Clin Obstet Gynaecol 2000;14:937-51
32. Robboy SJ, Bentley RC, Butnor K, Anderson MC. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000;108:779-84
33. Stewart E, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996;2:295-306 •• This article introduces what is known about the process of normal menstruation and angiogenesis in the uterus as a basis for understanding the molecular mechanisms underlying this process.
34. Sampson J. The blood supply of uterine myomata. Surg Gynecol Obstet 1912;14:215-30
35. Faulkner R. The blood vessels of the myomatous uteri. Am J Obstet Gynecol 1945;47:185-97
36. Farrer-Brown G, Beilby JO, Tarbit MH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971;38:743-51
37. Lanfer R, Golan A, Neuman M, et al. The effect of large uterine fibroids on urinary bladder function and symptoms. Am J Obstet Gynecol 1990;163:1139-41
38. Pron G, Bennett J, Common A, et al. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril 2003;79:120-7
39. Parker WH. Uterine myomas: management. Fertil Steril 2007;88:255-71 •• The author reviewed the current management alternatives, including watchful waiting; medical therapy; hysteroscopic myomectomy; endometrial ablation; laparoscopic myomectomy; abdominal myomectomy; abdominal, vaginal, and laparoscopic hysterectomy; uterine artery embolization; uterine artery occlusion; and focused ultrasound available to women with uterine myomas.
40. Parker WH. Etiology, symptomotology and diagnosis of uterine myomas. Fertil Steril 2007;87:725-36 •• The author reviews the currently available literature about the biology, etiology, symptoms, and diagnosis of uterine myomas.
41. Olive DL, Lindheim SR, Pritts EA. Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 2004;16:239-43
42. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005;308:1589-92 • The authors introduced the role of genetics, the extracellular matrix, and hormones in uterine myoma etiology.
43. Lee WL, Yuan CC, Wang PH. Positron emission tomography and uterine leiomyomas. Gynecol Oncol 2007;107:593-4
44. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414-8
45. Schwartz PE, Kelly MG. Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am 2006;33:183-98 • This article provides a clinicopathologic background about uterine leiomyosarcomas and answers common questions that obstetricians and gynecologists have about the management of rapidly growing fibroids and leiomyosarcomas.
46. Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta Obstet Gynecol Scand 2000;79:202-7
47. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 2000;121:1-8
48. Clayton RN. Gonadotrophin-releasing hormone: its actions and receptors. J Endocrinol 1989;120:11-9
49. Wen L, Tseng JY, Wang PH. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist. Taiwan J Obstet Gynecol 2006;45:173-5
50. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990;163:1114-9
51. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Br J Obstet Gynecol 2002;109:1097-108
52. Broekmans FJ, Hompes PGA, Heitbrink MA, et al. Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: standard-dose therapy followed by reduced-dose therapy. Am J Obstet Gynecol 1996;175:1208-16
53. Rutgers JL, Spong CY, Sinow R, Heiner J. Leuprolide acetate treatment and myoma arterial size. Obstet Gynecol 1995;86:386-8
54. Cirkel U, Ochs H, Schneider HP, et al. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study. Clin Ther 1992;14:37-50
55. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992;166:746-51
56. Watanabe Y, Nakamura G, Matsuguchi H, et al. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyoma in Japanese women. Fertil Steril 1992;58:66-71
57. Van Leusden HA. Symptom-free interval after triptorelin treatment of uterine fibroids: long-term results. Gynecol Endocrinol 1992;6:189-98
58. Chura JC, Downs LS Jr. Positron emission tomography and uterine leiomyomas: Authors' response. Gynecol Oncol 2007;107:594-5
59. Wang PH, Yang AH, Yuan CC, et al. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings. J Chin Med Assoc 1998;61:625-9
60. Chia CC, Huang SC, Chen SS, et al. Ultrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog. Taiwan J Obstet Gynecol 2006;45:124-8
61. Ito F, Kawamura N, Ichimura T, et al. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment. Fertil Steril 2001;75:125-30
62. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol 1993;24:1073-7
63. Mizutani T, Sugihara A, Nakamura K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 1998;83:1253-5
64. Higashijima T, Kataoka A, Nishda T, Yakushiji M. Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 1996;68:169-73
65. Huang SC, Chou CY, Lin YS, et al. Enhanced deoxyribonucleic acid damage and repair but unenhanced apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1997;177:417-24
66. Stovall TG, Muneyyirci-Delale O, Summitt RL, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. Obstet Gynecol 1995;86:65-71
67. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS. Predictions of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist. Fertil Steril 1992;58:413-5
68. Van Leusden HA. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol 1994;8:215-22
69. Matta WH, Shaw R, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989;96:200-6
70. Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 1990;53:1018-23
71. Wang PH, Horng HC, Cheng MH, et al. Standard and low-dose hormone therapy for postmenopausal women - focus on the breast. Taiwan J Obstet Gynecol 2007;46:127-34
72. Wang PH, Cheng MH, Chao HT, Chao KC. Effects of tibolone on the breast of postmenopausal women. Taiwan J Obstet Gynecol 2007;46:121-6
73. Maheux R, Lemay A, Blanchet P, et al. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991;6:500-5
74. Friedman AJ, Daly M, Juneau-Norcross M, et al. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin "add back" for 2 years. Hum Reprod 1994;9:1618-25
75. Ishimaru T, Samejima T, Masuzaki H. GnRHa and steroid add-back therapy for uterine myoma. Int J Gynecol Obstet 1995;48:221
76. Vercellini P, Sacerdote P, Trespidi L, et al. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study. Fertil Steril 1994;62:938-42
77. Palomba S, Francesco OJ, Russo T, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas. Hum Reprod 2004;19:1308-13
78. Palomba S, Affinito P, Di Carlo C, et al. Effects of long-term administration of tibolone plus GnRH-a in the treatment of uterine leiomyomata on effectiveness, vasomotor symptoms, bone mass and lipid profile. Fertil Steril 1999;72:889-95
79. Wang PH, Lee WL, Chao HT, et al. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa. J Chin Med Assoc 1999;62:294-9
80. Yoshioka N. Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri. Nippon Sanka Fujinka Gakkai Zasshi 1995;47:1255-60
81. Zullo F, Pellicano M, Di Carlo C, et al. Ultrasonograpic prediction of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1998;5:361-6
82. Kawamura N, Ito F, Ichimura T, et al. Correlation between shrinkage of uterine leiomyoma treated with buserelin acetate and histopathologic findings of biopsy specimen before treatment. Fertil Steril 1997;68:632-6
83. Furui T, Imai A, Takagi A, et al. Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. J Obstet Gynaecol 2000;20:504-6
84. Kettel LM, Murphy AA, Morales AJ, et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonists. Fertil Steril 1993;60:642-6
85. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001;(2):CD000547
86. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002;109:1097-108
87. Seracchioli R, Venturoli S, Colombo FM, et al. GnRH agonist treat before total laparoscopic hysterectomy for large uteri. J Am Assoc Gynecol Laparosc 2003;10:316-9
88. Felberbaum RE, Germer U, Ludwig M, et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 1998;13:1660-8
89. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, et al. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 1997;12:2028-35
90. Felberbaum RE, Kupker W, Krapp M, et al. Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing antagonist (Cetrotide). Reprod Biomed Online 2003;3:14-8
91. De Blok S, Oberye J. Rapid reduction of leiomyoma volume during treatment with the GnRH-antagonist ganirelix. Gynecol Endocrinol 2001;15:22
92. Yano T, Minaguchi H, Taketani Y, et al. Cetrorelix in the treatment of uterine leiomyomas. Gynecol Endocrinol 2001;15:46
93. Flierman PA, Oberye JJL, van der Hulst VPM, de Blok S. Rapid reduction of leiomyoma volume during treatment with the GnRH antagonist ganirelix. BJOG 2005;112:638-42
94. Kwon JY, Park KH, Park YN, Cho NH. Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells. Fertil Steril 2005;84:1526-8
95. Xiao BL, Zhou LY, Zhang XL, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-62
96. Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986;5:235-41
97. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000;65:585-92
98. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;(4):CD002126 •• To review the effectiveness and acceptability of progesterone or progestogen-releasing intrauterine devices in achieving a reduction in heavy menstrual bleeding.
99. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception 2007;75:S130-3
100. Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception 2003;67:277-80
101. Wang PH. Role of sex hormone receptors in ovulation. Taiwan J Obstet Gynecol 2005;44:16-25
102. Chao KC, Wang PH, Yen MS, et al. Role of estrogen and progesterone in the survival of ovarian tumors - a study of the human ovarian adenocarcinoma cell line OC-117-VGH. J Chin Med Assoc 2005;68:360-7
103. Wang PH, Chao HT. Reconsideration of tamoxifen use for breast cancer. Taiwan J Obstet Gynecol 2007;46:93-5
104. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 1997;94:14105-10
105. Fuchs-Young R, Howe S, Hale L, Miles R, Walker C. Inhibition of estrogen stimulated growth of uterine leiomyoma by selective estrogen receptor modulators. Mol Carcinog 1996;17:151-9
106. Walker CL, Burroughs KD, Davis B, et al. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyomas. J Soc Gynecol Investig 2000;7:249-56
107. Sadan O, Ginath S, Sofer D, et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomas - a pilot study. Eur J Obstet Gynecol Reprod Biol 2001;96:183-6
108. Lumsden MA, West CP, Baird DT. Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin Endocrinol Oxf 1989;31:335-43
109. Dilts PV Jr, Hopkins MP, Chang AE, Cody RL. Rapid growth of leiomyoma in patients receiving tamoxifen. Am J Obstet Gynecol 1992;166:167-8
110. Rullo S, Taqliaferri T, Bandiera F, et al. Uterine changes during tamoxifen therapy. Clin Exp Obstet Gynecol 1993;20:116-9
111. Porter KB, Tsibris JC, Porter GW, et al. Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 1998;179:1283-7
112. Palomaba S, Sammartino A, Di Carlo C, et al. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril 2001;76:38-43
113. Palomaba S, Orio F Jr, Morelli M, et al. Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study. J Clin Endocrinol Metab 2002;87:3603-8
114. Jirecek S, Lee A, Pavo I, et al. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 2004;81:132-6
115. Palomba S, Russo T, Orio F Jr, et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 2002;17:3213-9
116. Murphy AA, Castellano PZ. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr Opin Obstet Gynecol 1994;6:269-78
117. Yang Y, Zheng S, Li K. Treatment of uterine leiomyoma by two different doses of mifepristone. Chin J Obstet Gynecol 1996;31:624-6
118. Eisinger SH, Meldrum S, Fiscella K, et al. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-50
119. Murphy AA, Kettel LM, Morales AJ, et al. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J Clin Endocrinol Metab 1993;76:513-7
120. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficiency of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9:116-20
121. Chwalisz K, Parker L, Williamson S. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J Soc Gynecol Invest 2003;10:301A
122. Williams ARW, Critchley HOD, Osei J, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007;22:1696-704
123. Chwalisz K, Demanno D, Garg R, et al. Asopisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-32
124. Chwalisz K, Perez MC, DeManno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endoc Rev 2005;26:423-38 •• An extensive review of selective progesterone receptor modulator is provided in this review.
125. Chwalisz K, Demanno D, Garg R, et al. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 2004;22:113-9
126. Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005;20:1090-9
127. Chwalisz K, Larsen L, Mattia-Goldberg C, et al. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-412
128. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91:1296-304
129. Xu Q, Ohara N, Liu J, et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Endocrinol Metab 2007;293:1002-11
130. Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-1, TGFβ3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006;21:1869-77
131. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74:861-4
132. Grunberg SM. Role of antiprogestational therapy for meningiomas. Hum Reprod 1994;9:202-7
133. Lamverts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU486). J Clin Endocrinol Metab 1991;73:187-91
134. Heikinheimo O, Ranta S, Grunberg S, et al. Alterations in the pituitary-thyroid and pituitary-adrenal axes-consequences of long-term mifepristone treatment. Metabolism 1997;46:292-6
135. Pashkova VS, Erokhin IuA. Effects of androgens and gestagens on uterine myoma. Akush Ginekol 1991;1:46-9
136. Coutinho EM. Conservative treatment of uterine leiomyoma with the antiestrogen antiprogesterone R-2323. Int J Gynaecol Obstet 1981;19:357-60
137. Coutinho EM, Goncalves MT. Long-term treatment of leiomyomas with gestrinone. Fertil Steril 1989;51:939-46
138. Coutinho EM, Azadian-Boulanger G, Goncalves MT. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, an antiprogesterone. Am J Obstet Gynecol 1986;155:761
139. De Leo V, La Marca A, Morgante G. Short-term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest 1999;47:258-62
140. Coutinho EM. Treatment of large fibroids with large doses of gestrinone. Gynecol Obstet Invest 1990;30:44-7
141. Takebayashi T, Fujino Y, Umesaki N, Ogita S. Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma. Gynecol Obstet Invest 1995;39:207-11
142. Sharara FI, Nieman LK. Growth hormone receptor messenger ribonucleic acid expression in leiomyoma and surrounding myometrium. Am J Obstet Gynecol 1995;173:814-9
143. Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factor-I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol 1990;76:388-94
144. Chandrasekhar Y, Heiner J, Osuampke C. Insulin-like growth factor I and II binding in human myometrium and leiomyomas. Am J Obstet Gynecol 1992;166:64-9
145. De Leo V, La Marca A, Morgante G, et al. Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata. Fertil Steril 2001;75:632-3
146. Melli MS, Farzadi L, Madarek EO. Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. Saudi Med J 2007;28:445-50
147. Rein MS. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 2000;108:791-3
148. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994;78:736-43
149. Sumitani H, Shozu M, Segawa T, et al. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000;141:3852-61
150. Shozu M, Sumitani H, Segawa T, et al. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate. J Clin Endocrinol Metab 2001;86:5405-11
151. Shozu M, Murakami K, Segawa T, et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril 2003;79:628-31
152. Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, et al. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol 2007;110:643-9
153. Creveling CR. The role of catechol-O-methyltransferase in the inactivation of catecholestrogen. Cell Mol Neurobiol 2003;23:289-91
154. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyomata. Steroids 1981;37:195-203
155. Salama SA, Ho SL, Wang HQ, et al. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyoma. Fertil Steril 2006;86:259-62
156. Bradlow LH. 2-Hydroxyestrerone: the "good" estrogen. J Endocrinol 1996;150:S259-65
157. Vandewalle B. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46
158. Banerjee SN, Sengupta K, Banerjee S, et al. 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-alpha: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells. Neoplasia 2003;5:417-26
159. Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265-75
160. Paquette B, Bisson M, Baptiste C, et al. Invasiveness of breast cancer cells MDA-MB-231 through extracellular matrix is increased by the estradiol metabolite 4-hydroxyestradiol. Int J Cancer 2005;113:706-11
161. McLeod HL, Fang L, Luo X, et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J Pharmacol Exp Ther 1994;270:26-9
162. Al-Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 2006;13:136-44
163. Tsibris JCM, Porter KB, Nicosia SF, et al. Retinoic acid involvement in leiomyoma development: an animal model. J Soc Gynecol Invest 1996;3(S2):29A
164. Tontonoz P, Hu E, Graves RA, et al. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224-34
165. Tsibris JCM, Porter KB, Jazayeri A, et al. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor γ, retinoid X receptor α, and all-trans retinoic acid than myometrium. Cancer Res 1999;59:5737-44
166. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006;195:415-20
167. Catherino W, Salama A, Potlog-Nahari C, et al. Gene expression studies in leiomyomata: new directions for research. Semin Reprod Med 2004;22:83-90
168. Tsibris JC, Segars J, Coppola D, et al. Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertil Steril 2002;78:114-21 • The authors used microarray analysis as an unbiased approach to identify genes involved in the induction and growth of uterine leiomyomata.
169. Leppert PC, Baginski T, Prupas C, et al. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril 2004;82:1182-7
170. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685-700
171. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-β signal transduction and mesangial cell gibrogenesis. Am J Physiol Renal Physiol 2003;284:243-52
172. Dou Q, Zhao Y, Tarnuzzer RW, et al. Suppression of transforming growth factor beta (TGF-β) and TGF-β receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab 1996;81:3222-30
173. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-8
174. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF β3) and altered responses to the antiproliferative effects of TGF-β. J Clin Endocrinol Metab 2001;86:913-20
175. Luo X, Ding L, Xu J, et al. Leiomyoma and myometrial gene expression profiles and their response to gonadotropin releasing hormone analogue (GnRHa) therapy. Endocrinology 2005;146:1074-95
176. Lee BS, Margolin SB, Nowak PA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998;83:219-23
177. Stewart EA, Disalvo D, Sharif NA, et al. Pirfenidone for the treatment of uterine leiomyomas: pilot study data. J Soc Gynecolog Invest 1999;6:229A
178. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a crit95; 172:14-8
179. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell number antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998;83:2192-8
180. Matsuo H, Maruo T, Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 1997;82:293-9
181. Kurachi O, Matsuo H, Maruo T. Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone. J Clin Endocrinol Metab 2001;86:2275-80
182. Gao Z, Matsuo H, Wang Y, et al. Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 2001;86:5593-9
183. Lee EJ, Kong G, Lee SH, et al. Profiling of differentially expressed genes in human uterine leiomyomas. Int J Gynecol Cancer 2005;15:146-54
184. Xu Q, Ohara N, Sitruk-Ware R, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and (adenosine 5′-diphosphate- ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90:953-61
185. Xu Q, Ohara N, Maruo T, et al. Progesterone receptor modulator CDB2914 down-regulates VEGF, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408-16
186. Cheng MH, Chao HT, Wang PH. Unusual clinical presentation of uterine myomas. Taiwan J Obstet Gynecol 2007;46:323-4
187. Tsai YJ, Yeat SK, Jeng CJ, Chen SC. Torsion of a uterine leiomyoma. Taiwan J Obstet Gynecol 2006;45:333-5
188. Cheng MH, Chao HT, Wang PH. Medical treatment for uterine myomas. Taiwan J Obstet Gynecol 2008;47:In press
189. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33 •• The WHI trial used a "global index" that included CHD, stroke, pulmonary embolism, invasive breast cancer, endometrial cancer, colorectal cancer, hip fracture, and death from other causes to conclude that the risks of therapy with EPT outweighed the benefits.
190. Lee WL, Chao HT, Wang PH. Transdermal 17β-estradiol for preventing postmenopausal bone loss. J Chin Med Assoc 2007;70:464-5
191. Mendelsohn RH, Karas RH. HRT and the young at heart. N Engl J Med 2007;356:2639-41.